医学
安慰剂
系统性红斑狼疮
临床终点
红斑狼疮
内科学
泌尿科
随机对照试验
免疫学
病理
抗体
替代医学
疾病
作者
Joan T. Merrill,Yoshiya Tanaka,David D’Cruz,Karina Vilá-Rivera,Daniel Siri,Xiaofeng Zeng,Amit Saxena,Martin Aringer,Kristin M. D’Silva,Ling Cheng,Mohamed‐Eslam F. Mohamed,Lucia Siovitz,Sumit Bhatnagar,Marie‐Claude Gaudreau,Thao Doan,Alan Friedman
摘要
Upadacitinib 30 mg alone or in combination with elsubrutinib (ABBV-599 high dose) demonstrated significant improvements in SLE disease activity and reduced flares and were well tolerated through 48 weeks.
科研通智能强力驱动
Strongly Powered by AbleSci AI